Sugi Predict

Sugi Predict / Compounds / SCHEMBL111536

SCHEMBL111536

SCHEMBL111536

COc1ccc(I)cc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.59
▸ CYP3A4 P08684 2/20 0.59
▸ MEN1 O00255 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ THRB P10828 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ GAA P10253 2/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ TDP1 Q9NUW8 3/20 0.48
▸ APP P05067 2/20 0.48
▸ ADRA2B P18089 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ SLC6A2 P23975 1/20 0.47
▸ SLC6A4 P31645 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ TUBB4A P04350 3/20 0.46
▸ TUBB P07437 3/20 0.46
▸ TUBA3C P0DPH7 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31722598 1.00 ALDH1A1 (0.59) ALDH1A1CYP3A4MEN1MAPTTHRB
SCHEMBL4169962 0.82 ALDH1A1 (0.61) ALDH1A1CYP3A4MEN1MAPTTHRB
SCHEMBL31277237 0.78 CA2 (0.54) ALDH1A1CYP3A4APPTUBB4ATUBB
SCHEMBL470124 0.78 CA2 (0.54) ALDH1A1CYP3A4APPTUBB4ATUBB
SCHEMBL1612735 0.77 GAA (0.46) ALDH1A1MEN1MAPTKMT2AGAA
SCHEMBL31607677 0.76 ALDH1A1 (0.67) ALDH1A1CYP3A4MEN1MAPTTHRB
SCHEMBL482383 0.76 CA2 (0.41) ALDH1A1CYP3A4LMNAAPPTSHR
SCHEMBL212391 0.76 ALDH1A1 (0.64) ALDH1A1CYP3A4MEN1MAPTTHRB
SCHEMBL30839809 0.76 ALDH1A1 (0.67) ALDH1A1CYP3A4MEN1MAPTTHRB
SCHEMBL15514306 0.76 ALDH1A1 (0.64) ALDH1A1CYP3A4MEN1MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 — — US disclosed
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 — — US disclosed
EP-3992176-B1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2025-08-27 — — EP disclosed
EP-4548937-A1 ANTIBODY-DRUG COMPLEX Eisai R&D Management Co., Ltd. (JP) 2025-05-07 — — EP disclosed
US-20240148895-A1 ANTIBODY-DRUG CONJUGATE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-05-09 — — US disclosed
WO-2024043319-A1 ANTIBODY-DRUG COMPLEX エーザイ・アール・アンド・ディー・マネジメント株式会社 2024-02-29 — — WO disclosed
US-20230382928-A1 EUROPIUM(III) COMPLEXES AS PH SENSORS CISBIO BIOASSAYS (FR) 2023-11-30 — — US disclosed
US-20230382928-A1 EUROPIUM(III) COMPLEXES AS PH SENSORS CISBIO BIOASSAYS (FR) 2023-11-30 — — US disclosed
US-20220388955-A1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 — — US disclosed
WO-2022090284-A1 EUROPIUM(III) COMPLEXES AS PH SENSORS CISBIO BIOASSAYS (FR) 2022-05-05 — — WO disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 — — US disclosed
WO-2009021750-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-19 — — WO disclosed
WO-2009021750-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-19 — — WO disclosed
US-7470723-B2 Diphenylethylene compounds and uses thereof CELGENE CORPORATION (US) 2008-12-30 — — US disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 — — WO disclosed
EP-1799634-A2 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2007-06-27 — — EP disclosed
WO-2006026747-A2 DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF CELGENE CORPORATION (US) 2006-03-09 — — WO disclosed
US-20050107339-A1 Diphenylethylene compounds and uses thereof CELGENE CORPORATION 2005-05-19 — — US disclosed
WO-2004041799-A1 5- (SUBSTITUTED PHENYL) -THIADIAZOLIDINE-3-ONES AND THEIR USE AS PTP1B ASTRAZENECA AB (SE) 2004-05-21 — — WO disclosed
US-4507237-A DISPERSE AND BASIC DYES HODOGAYA CHEMICAL CO., LTD. (JP) 1985-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107339-A1 Diphenylethylene compounds and uses thereof VHL, TNF, PTGES ALDH1A1 124/4885CYP3A4 356/4885MEN1 1398/4885
US-20230382928-A1 EUROPIUM(III) COMPLEXES AS PH SENSORS NCS1, GALR3, TAS1R3 ALDH1A1 3455/4885CYP3A4 877/4885MEN1 47/4885
US-20220388955-A1 EP2 ANTAGONIST PTGER2, PTGER1, PTGES2 ALDH1A1 1473/4885CYP3A4 3480/4885MEN1 2473/4885
US-20240148895-A1 ANTIBODY-DRUG CONJUGATE ANTXR2, FCGR1A, HAX1 ALDH1A1 927/4885CYP3A4 724/4885MEN1 910/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 ALDH1A1 571/4885CYP3A4 1190/4885MEN1 3460/4885
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A ALDH1A1 3714/4885CYP3A4 4706/4885MEN1 3954/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885CYP3A4 3900/4885MEN1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback